Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1276 to 1290 of 1766 results for patient safety

  1. Evidence on the efficacy of focal resurfacing implants to treat articular cartilage damage in the knee is limited in quality and quantity. Short-term evidence shows no major safety concerns, but long-term evidence on safety is limited in quality and quantity. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    quality and quantity. Short-term evidence shows no major safety concerns, but long-term evidence on safety is limited in...

    Research recommendation
    Published
    7 September 2022

  2. Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.  Find out  what only in research means on the NICE website .

    Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major...

    Research recommendation
    Published
    10 August 2020

  3. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA995

  4. Cyanoacrylate glue for hernia mesh fixation (MIB301)

    NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .

    Medtech innovation briefing
    Published
    5 July 2022

  5. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  6. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA951

  7. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1003

  8. Spasticity in under 19s: management (CG145)

    This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.

    Clinical guideline
    Last updated
    29 November 2016
    View recommendations

    Sections for CG145

  9. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA892

  10. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTG665)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

    HealthTech guidance
    Last updated
    10 August 2023
    View recommendations

    Sections for HTG665

  11. NICE encourages further research on endovascular aneurysm sealing for abdominal aortic aneurysmthis procedure in the form of controlled clinical trials, observational studies and analysis of registry data. Details about patient selection, including anatomical details, should be clearly documented.Research should compare the procedure with conventional stent graft endovascular aneurysm repair. All complications should be reported. Long-term outcomes should be described as data become available. NICE may update the guidance on publication of further evidence.

    trials, observational studies and analysis of registry data. Details about patient selection, including anatomical details, should be...

    Research recommendation
    Published
    21 March 2016

  12. Evidence on the safety and efficacy of biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG752/01 Question Evidence on the safety and efficacy of biodegradable spacer insertion to reduce rectal toxicity...

    Research recommendation
    Published
    9 March 2023

  13. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    HealthTech guidance
    Published
    22 August 2012
    View recommendations

    Sections for HTG290

  14. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

    HealthTech guidance
    Published
    27 January 2022
    View recommendations

    Sections for HTG607

  15. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

    Medtech innovation briefing
    Published
    30 January 2018